microdosing with glp 1 THE PCCA BLOG Should Everyone be Microdosing GLP-1s?

They represent a lasting shift in cardiometabolic care, with actuarial implications that will unfold over years

First, a substantial portion of the mechanistic and translational data derives from preclinical studies or small human cohorts, which may not fully capture understudied aspects of aging that vary across populations

Multiple sclerosis is a chronic autoimmune condition affecting the central nervous system

However, analysis of trial data from five long-acting GLP-1 agonists (exenatide once weekly, taspoglutide, albiglutide, LY2189265 and CJC-1134-PC) revealed that they were more likely than shorter-acting formulations to raise the heart rate (Robinson et al., 2013)

We cant stress this enough: the source is everything